Nuvelo Announces Presentations on NU206 and rNAPc2 at 2008 American Association for Cancer Research Annual Meeting

SAN CARLOS, Calif., April 9, 2008 /PRNewswire-FirstCall/ -- Nuvelo, Inc. (Nasdaq: NUVO ) today announced that preclinical data evaluating the mechanism of action and therapeutic potential of NU206 (R-spondin1) for chemotherapy or radiation-induced oral mucositis, and preclinical data evaluati...

Ebola Treatment Shows Promise

...a factor known to inhibit blood coagulation called rnapc2 led to increased survival rates. The Ebola vi... wondered if the disease could be stopped by using rnapc2 to inhibit the blood coagulation pathway. Res... than replication of the infectious agent.” Noting rnapc2 has a good safety profile in humans, they believe ...

rNAPc2 in Medical Technology

Nuvelo Announces Presentation on rNAPc2 at American College of Cardiology 56th Annual Scientific Session

SAN CARLOS, Calif., March 19, 2007 /PRNewswire-FirstCall/ -- Nuvelo, Inc. today announced that clinical data from the ANTHEM (Anticoagulation with rNAPc2 To Help Eliminate MACE)/TIMI 32 Phase 2 trial looking at recombinant nematode anticoagulant protein c2 (rNAPc2) in patients with non-ST-elevatio...

Nuvelo Announces Publication of Phase 2 rNAPc2 Study Results in Journal of American College of Cardiology

SAN CARLOS, Calif., June 19, 2007 /PRNewswire-FirstCall/ -- Nuvelo, Inc. today announced the publication of the Phase 2 proof-of-concept data from the Anthem (Anticoagulation with rNAPc2 To Help Eliminate MACE)/TIMI 32 clinical trial (N=255) in the June 26th issue of the Journal of of Cardiology (...

Nuvelo Announces Presentations on rNAPc2 and NU172 at the XXIst Congress of the International Society on Thrombosis and Haemostasis

SAN CARLOS, Calif., July 5 /PRNewswire-FirstCall/ -- Nuvelo, Inc. (Nasdaq: NUVO) today announced that data from the ANTHEM (Anticoagulation with rNAPc2 To Help Eliminate MACE)/TIMI 32 Phase 2 trial looking at recombinant nematode anticoagulant protein c2 (rNAPc2) in patients with acute coronary sy...

Nuvelo Announces Publication of NU206 Study Results in Gastroenterology

...itor for use as a short- acting anticoagulant during medical or surgical procedures. Nuvelo is also advancing an emerging oncology pipeline, including rnapc2 which is in Phase 2 testing for potential use as a cancer therapy, as well as NU206 a preclinical candidate for the potential treatment of chemotherap...

Nuvelo Announces Publication of Preclinical Study Results Demonstrating the Potential of NTB-A as a New Target for Leukemia and Lymphomas

...bitor for use as a short-acting anticoagulant during medical or surgical procedures. Nuvelo is also advancing an emerging oncology pipeline, including rnapc2 which is in Phase 2 testing for potential use as a cancer therapy, as well as NU206 for the potential treatment of chemotherapy/radiation therapy-indu...